KalVista Pharmaceuticals, Inc. presents five posters at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas, United States.
“The real-world data presented at AAAAI highlight the significant treatment burden and anxiety associated with existing injectable on-demand therapies, and the potential for sebetralstat, an investigational oral plasma kallikrein inhibitor, to improve the treatment experience for people living with HAE,” says Andrew Crockett, CEO of KalVista. “Additionally highlighting this potential are the data from our phase 2 trial assessing sebetralstat for on-demand of HAE attacks demonstrating that early treatment decreased cumulative attack and symptom severity compared to placebo, as well as new data supporting continued advancement of our orally disintegrating tablet formulation.”
All five presentations can be found at www.kalvista.com/healthcare-providers/publications.
(Source: KalVista)
